Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With
Adenocarcinoma of Lung
/ drug therapy
Carcinoma, Non-Small-Cell Lung
/ drug therapy
ErbB Receptors
/ genetics
Humans
Lung Neoplasms
/ drug therapy
Protein Kinase Inhibitors
/ therapeutic use
Protein-Tyrosine Kinases
/ genetics
Proto-Oncogene Proteins
/ genetics
Proto-Oncogene Proteins c-ret
/ therapeutic use
Reactive Oxygen Species
/ therapeutic use
Receptor Protein-Tyrosine Kinases
/ genetics
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
12
10
2022
Statut:
ppublish
Résumé
Local therapy prolongs progression-free survival in patients with oligometastatic non-small-cell lung cancers treated with chemotherapy. We previously reported that local therapy also prolongs survival and time to next therapy in patients on tyrosine kinase inhibitors (TKIs) for Patients with advanced Sixty-one patients with Local therapy for progression on ALK, ROS1, or RET TKIs is associated with clinically meaningful time on continued TKI therapy beyond progression, especially earlier in the course of disease.
Identifiants
pubmed: 36201714
doi: 10.1200/PO.22.00024
pmc: PMC9848570
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins
0
Reactive Oxygen Species
0
ErbB Receptors
EC 2.7.10.1
Protein-Tyrosine Kinases
EC 2.7.10.1
Proto-Oncogene Proteins c-ret
EC 2.7.10.1
RET protein, human
EC 2.7.10.1
ROS1 protein, human
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200024Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Lung Cancer. 2015 Dec;90(3):477-83
pubmed: 26604031
J Thorac Oncol. 2013 May;8(5):654-7
pubmed: 23584297
Clin Lung Cancer. 2017 Nov;18(6):e369-e373
pubmed: 28465010
J Cancer. 2019 Jan 1;10(2):522-529
pubmed: 30719148
J Clin Oncol. 2013 Nov 1;31(31):3987-96
pubmed: 24101047
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
J Clin Oncol. 2015 Jun 10;33(17):1881-8
pubmed: 25624436
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):892-8
pubmed: 24462383
JAMA Oncol. 2018 Jan 11;4(1):e173501
pubmed: 28973074
N Engl J Med. 2020 Aug 27;383(9):813-824
pubmed: 32846060
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
J Thorac Oncol. 2012 Dec;7(12):1807-1814
pubmed: 23154552
J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49
pubmed: 9011700
Crit Rev Oncol Hematol. 2020 Apr;148:102894
pubmed: 32062314
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Expert Rev Anticancer Ther. 2016 Jun;16(6):615-23
pubmed: 27109446
Lung Cancer. 2011 Dec;74(3):457-61
pubmed: 21571388
Radiat Oncol. 2021 Jan 6;16(1):4
pubmed: 33407611
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Clin Oncol (R Coll Radiol). 2017 Sep;29(9):568-575
pubmed: 28499791
J Thorac Oncol. 2013 Mar;8(3):346-51
pubmed: 23407558
Lung Cancer. 2013 Sep;81(3):440-444
pubmed: 23810573
Lancet Oncol. 2008 Jul;9(7):621-8
pubmed: 18565793
Radiol Med. 2019 Jul;124(7):662-670
pubmed: 30771218
Radiother Oncol. 2020 Jul;148:157-166
pubmed: 32388150
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
Ann Oncol. 2014 Feb;25(2):415-22
pubmed: 24478318